Development of a biochip-based assay integrated in a global strategy for identification of fusion transcripts in acute myeloid leukemia: a work flow for acute myeloid leukemia diagnosis

International Journal of Laboratory Hematology
S GiusianoJ Gabert

Abstract

Three major types of rearrangements are involved in acute myeloid leukemias (AML): t(8;21)(q22;q22), inv(16)(p13q22), and 11q23/MLL abnormalities. Their precise identification becomes essential for diagnosis, prognosis, and therapeutic choices. Resulting fusion transcripts (FT) are also powerful markers for monitoring the efficacy of treatment, the minimal residual disease (MRD) and could become therapeutic targets. Today, the challenge is to propose an individual follow-up for each patient even for those with a rare fusion event. In this study, we propose a biochip-based assay integrated in a global strategy for identification of rare FT in AML, after fluorescence in situ hybridization detection, as described by the World Health Organization classification. Using cell lines, we developed and validated a biochip-based assay called the AMLFusionChip that identifies every FT of AML1-ETO, CBFbeta-MYH11 as well as MLL-AF9, MLL-ENL, MLL-AF6, and MLL-AF10. The original design of our AMLFusionChip.v01 enables the identification of these FT wherever the breakpoint on the partner gene may be. In case of biochip negative result, our 3'RACE amplification strategy enables to clone and then sequence the new translocation partner. This AMLFu...Continue Reading

References

Sep 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·J CorralA Karpas
Oct 23, 1997·Proceedings of the National Academy of Sciences of the United States of America·M D MegonigalC A Felix
Aug 2, 2000·Proceedings of the National Academy of Sciences of the United States of America·M D MegonigalC A Felix
Dec 17, 2002·Leukemia & Lymphoma·Jennifer StulbergRichard A Wells
Jun 14, 2003·Leukemia & Lymphoma·Eiichi IshiiMariko Eguchi
Jun 21, 2003·Clinical Chemistry·Run Zhang ShiJanet D Rowley
Jan 23, 2004·The Journal of Molecular Diagnostics : JMD·ShriHari S KadkolFarhad Ravandi
Jan 1, 2005·Proceedings of the National Academy of Sciences of the United States of America·Claus MeyerRolf Marschalek
Aug 8, 2006·Biotechnology Journal·Claus MeyerRolf Marschalek
Nov 25, 2006·Hematology·Miguel A Sanz
Sep 10, 2008·Blood·Janet D Rowley
Mar 6, 2009·Leukemia·C MeyerR Marschalek

❮ Previous
Next ❯

Citations

Apr 20, 2016·Frontiers in Microbiology·Jaewoo BaiJu-Hoon Lee

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.